: Many analysts, including those from Barclays and Goldman Sachs , see the current price (near its 52-week low of ~$59) as an attractive entry point with predicted upsides ranging from 37% to over 50%.

: Fresh data from the Heart Rhythm 2026 conference continues to support the safety and efficacy of key franchises like FARAPULSE and WATCHMAN . The Sell Case: Rising Risks

: Despite trimming price targets, the consensus remains a Moderate Buy .

: The company reported Q1 2026 revenue of $5.20B and adjusted EPS of $0.80, both slightly beating market expectations.

Create Playlist

Bsx Stock Buy Or Sell [SAFE]

: Fresh data from the Heart Rhythm 2026 conference continues to support the safety and efficacy of key franchises like FARAPULSE and WATCHMAN . The Sell Case: Rising Risks bsx stock buy or sell

: Despite trimming price targets, the consensus remains a Moderate Buy . : Many analysts, including those from Barclays and

: The company reported Q1 2026 revenue of $5.20B and adjusted EPS of $0.80, both slightly beating market expectations. : Many analysts